Ioana Lancranjan

Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly

To evaluate the efficacy and safety of a long‐acting preparation of the somatostatin analogue octreotide, Sandostatin‐LAR® (SMS‐LAR) for the treatment of acromegaly.

RAPID AND LONG‐LASTING SUPPRESSION OF PROLACTIN SECRETION AND SHRINKAGE OF PROLACTINOMAS AFTER INJECTION OF LONG‐ACTING REPEATABLE FORM OF BROMOCRIPTINE (PARLODEL LAR)

Five patients with PRL‐secreting macroadenoma and nine patients with PRL‐secreting microadenoma or idiopathic hyperprolactinaemia were treated with monthly administrations of long‐acting bromocriptine suitable for repeatable injections (Parlodel LAR) for 1–12 cycles of treatment. A significant shrinkage of tumour mass and the recovery of visual field defects were observed in patients with macroprolactinoma. Plasma PRL levels decreased to 16.8 and 18.1% of pretreatment values, in macroprolactinoma and idiopathic or microadenoma‐tous hyperprolactinaemic subjects, respectively, during the first cycle of treatment, reaching the normal range in three patients of each group. During the following cycles of treatment, two patients with macroprolactinoma and one patient with idiopathic or microadenomatous hyperprolactinaemia became normoprolactinaemic. Adverse reactions generally did not last beyond the first days of administration and decreased with the progression of the treatment. In conclusion, its effectiveness and the fact that it is well tolerated, may suggest that this form of bromocriptine may be used as a first therapeutic approach for patients with PRL‐secreting adenomas, particularly when shrinkage of a macroadenoma is urgently required.

EFFECT OF BROMOCRIPTIN ON THE ENDOCRINE SYSTEM AND FETAL DEVELOPMENT

A preliminary report on the endocrine effects of bromocriptin (CB 154) on pituitary hormones has already been published (del Pozo et al., 1973). In the mean time these studies have been extended to consider other endocrine parameters. This paper illustrates the effect of acute and chronic treatment with bromocriptin on growth hormone (hGH), placental Iactogen (hPL), thyro trophin (TSH), insulin (IRI), cortisol, aldosterone, and free fatty acids (FFA). In addition, observations on the action of bromocriptin on pregnancy and fetal development are presented.

Effect of two serotonin antagonists on prolactin release induced by breast stimulation in postpartum women.

The possible role of serotonin on prolactin (PRL) secretion was investigated by measuring PRL plasma levels before and after mechanical breast stimulation in puerperal women. Two serotonin antagonists

Control of prolactin‐secreting macroadenomas with parenteral, long‐acting bromocriptine in 30 patients treated for up to 3 years

OBJECTIVE We investigated the effect of intramuscular injections of long‐acting bromocriptine in patients with macroadenomas.